Targeting Oncostatin M-Receptor to Suppress Metastasis and Therapy Failure

靶向制瘤素 M 受体抑制转移和治疗失败

• 批准号: 10211081
• 负责人: MARK W. JACKSON
• 金额: $ 41.28万
• 依托单位: CASE WESTERN RESERVE UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2021
• 资助国家: 美国
• 起止时间: 2021-03-04 至 2026-02-28
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10211081
• 关键词: Binding; Breast Cancer Cell; Breast cancer metastasis; CBL gene; Cell Culture Techniques; Cells; Clinical; Combined Modality Therapy; Complex; Disease; Drug Tolerance; Equilibrium; Gene Expression; Generations; Genes; Genetic Transcription; Goals; Human; Immune; Immune checkpoint inhibitor; Immune system; Immuno-Chemotherapy; Immunosuppressive Agents; Inflammatory; Interferon-beta; Lead; Link; MADH3 gene; Maintenance; Mediating; Mesenchymal; Molecular; Neoplasm Metastasis; Patient-Focused Outcomes; Patients; Phosphorylation; Plant Roots; Population; Production; Recurrence; Recurrent Malignant Neoplasm; Relapse; Repression; Resistance; STAT1 gene; STAT2 gene; STAT3 gene; Seeds; Signal Transduction; Testing; Treatment Failure; Tumor Immunity; Viral; base; cancer cell; cancer cell differentiation; cancer invasiveness; cancer recurrence; chemotherapy; cytokine; immune system function; improved; improved outcome; mimicry; mouse model; nanoparticle; novel; novel therapeutic intervention; oncostatin M; prevent; programs; promoter; receptor; sensor; standard of care; stem; stem-like cell; therapy resistant; transcription factor; triple-negative invasive breast carcinoma; tumor; tumor microenvironment

ABSTRACT The metastatic spread of cancer cells and recurrence are intimately linked to therapy failure, which remains an important clinical challenge for patients with metastatic Triple Negative Breast Cancer (TNBC). Two important factors that regulate TNBC metastasis and recurrence are: (i) the differentiation status of the cancer cells, and (ii) the functionality of the immune system within the tumor microenvironment (TME). Both the cancer cells and the immune cells are highly influenced by the cytokines Oncostatin M (OSM) and Interferon-beta (IFNB). We find that the actions of OSM and IFNB oppose one another in regulating both cancer cell differentiation and immune system function within the TME. OSM and its receptor (OSMR) are frequently upregulated in aggressive, metastatic and therapy-resistant recurrent cancers, such as TNBC. Mechanistically, OSM/OSMR elicits robust activation of STAT3, which forms a transcriptional complex with SMAD3, and induces stem-like/mesenchymal programs that enhance TNBC aggressiveness and resistance to chemo- and immuno-therapy. Moreover, the cooperation of STAT3 and SMAD3 on co-dependent gene promoters produces a pro-inflammatory, tumor- promoting TME by suppressing the production of immune-activating IFNB and inducing immune-inhibitory cytokines. Restoring IFNB signaling prevents and reverses stem-like/mesenchymal programming stimulated by OSMR and STAT3/SMAD3. Thus, the cooperation between STAT3 and SMAD3 to inactivate IFNB :STAT1/2 signaling axis represents a key step in metastatic progression and tumor recurrence. Based on these and other compelling findings, we will test the hypothesis that the relative balance between OSM:STAT3/SMAD3 and IFNB :STAT1/2 signaling in both TNBC cells and immune cells dictates metastatic relapse and ultimately, patient outcomes. We’ll test this hypothesis in two Specific Aims: Aim 1 will determine how IFNB suppresses OSMR- mediated STAT3/SMAD3 co-dependent gene expression; Aim 2 will define how OSMR/ERK signaling activates STAT3/SMAD3 to drive stem-like/mesenchymal reprogramming and the suppression of IFNB/ISGs. Together, the results from our studies will provide a greater understanding of the molecular mechanisms by which OSM and IFNB antagonize one another and test novel therapeutic approaches to shift the balance towards active IFNB :STAT1/2 and away from OSMR:STAT3/SMAD3 in both TNBC and immune cells, with the goal of improving outcomes for patients with metastatic TNBC.

抽象的 癌细胞的转移扩散和复发与治疗失败密切相关，这仍然是一个问题 转移性三阴性乳腺癌 (TNBC) 患者面临的重要临床挑战有两个重要的挑战。 调节 TNBC 转移和复发的因素是：(i) 癌细胞的分化状态，以及 (ii) 免疫系统的功能 肿瘤微环境（TME）。 我们发现，免疫细胞受细胞因子制瘤素 M (OSM) 和干扰素-β (IFNB) 的影响很大。 OSM 和 IFNB 在调节癌细胞分化和免疫方面的作用是相反的 TME 及其受体 (OSMR) 内的系统功能在攻击性、 转移性和治疗耐药的复发性癌症，如 TNBC 从机制上讲，OSM/OSMR 能产生强大的效果。 STAT3 的激活，与 SMAD3 形成转录复合物，并诱导干细胞样/间充质细胞 增强 TNBC 侵袭性和对化疗和免疫治疗的抵抗力的计划。 STAT3 和 SMAD3 在共同依赖的基因启动子上的合作产生促炎、肿瘤- 通过抑制免疫激活 IFNB 的产生并诱导免疫抑制来促进 TME 恢复 IFNB 信号传导可预防和逆转由细胞因子刺激的干细胞样/间质编程。 OSMR 和 STAT3/SMAD3 因此，STAT3 和 SMAD3 之间的合作使 IFNB :STAT1/2 失活。 基于这些和其他因素，信号轴代表了转移进展和肿瘤复发的关键步骤。 有影响力的发现，我们将检验 OSM:STAT3/SMAD3 和 TNBC 细胞和免疫细胞中的 IFNB :STAT1/2 信号传导决定转移复发并最终导致患者 我们将在两个具体目标中检验这一假设：目标 1 将确定 IFNB 如何抑制 OSMR-。 介导的 STAT3/SMAD3 共依赖性基因表达；目标 2 将定义 OSMR/ERK 信号传导如何激活 STAT3/SMAD3 共同驱动干细胞/间质重编程并抑制 IFNB/ISG。 我们的研究结果将有助于更好地理解 OSM 的分子机制 和 IFNB 相互拮抗并测试新的治疗方法以将平衡转向主动 TNBC 和免疫细胞中 IFNB :STAT1/2 并远离 OSMR:STAT3/SMAD3，目的是改善 转移性 TNBC 患者的结局。